RESUMEN
PURPOSE: Circulating microRNAs represent a reservoir for biomarker discovery. Our objective was to profile the change in human circulating microRNA associated with recreational use of alcohol at a social event. MATERIAL AND METHODS: Blood was collected from healthy volunteers (N = 16) before and after recreational consumption of alcohol (ethanol). Biochemistry, hematology and ethanol measurements were performed. The change in the serum small RNA fraction was quantified by RNA sequencing. RESULTS: Blood ethanol was undetectable at study entry in all subjects [<10 mg/dL]. After consuming alcohol the median concentration was 89 mg/dL [IQR: 71-138. Min-max 20-175]. There were no changes in biochemistry and hematology parameters. Serum RNA sequencing identified 1371 small RNA species (1305 microRNAs). There were significant increases [adjusted p-value <0.05, fold increase 2 or more] in 265 microRNAs, around a fifth of the total [median fold increase 2.3 [IQR: 2.1-2.5; Max: 3.7]]. miR-185-5p decreased following alcohol exposure [adjusted p-value <0.05, fold decrease 2 or more]. CONCLUSIONS: The microRNA composition of human serum is dynamic and environmental factors may have a significant impact. Within its context of use the fold change 'signal' of a microRNA must be large enough to negate the risk of false results due to background 'noise'.
Asunto(s)
Consumo de Bebidas Alcohólicas/sangre , MicroARNs/sangre , Recreación , Adulto , Consumo de Bebidas Alcohólicas/genética , Etanol/sangre , Femenino , Voluntarios Sanos , Humanos , Relaciones Interpersonales , Masculino , Análisis de Secuencia de ARNRESUMEN
Paracetamol (acetaminophen) is the most commonly used drug in the world, with a long record of use in acute and chronic pain. In recent years, the benefits of paracetamol use in chronic conditions has been questioned, notably in the areas of osteoarthritis and lower back pain. Over the same period, concerns over the long-term adverse effects of paracetamol use have increased, initially in the field of hypertension, but more recently in other areas as well. The evidence base for the adverse effects of chronic paracetamol use consists of many cohort and observational studies, with few randomized controlled trials, many of which contradict each other, so these studies must be interpreted with caution. Nevertheless, there are some areas where the evidence for harm is more robust, and if a clinician is starting paracetamol with the expectation of chronic use it might be advisable to discuss these side effects with patients beforehand. In particular, an increased risk of gastrointestinal bleeding and a small (~4 mmHg) increase in systolic blood pressure are adverse effects for which the evidence is particularly strong, and which show a degree of dose dependence. As our estimation of the benefits decreases, an accurate assessment of the harms is ever more important. The present review summarizes the current evidence on the harms associated with chronic paracetamol use, focusing on cardiovascular disease, asthma and renal injury, and the effects of in utero exposure.
Asunto(s)
Acetaminofén/efectos adversos , Analgésicos no Narcóticos/efectos adversos , Dolor Crónico/tratamiento farmacológico , Acetaminofén/administración & dosificación , Acetaminofén/normas , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/epidemiología , Lesión Renal Aguda/prevención & control , Analgésicos no Narcóticos/administración & dosificación , Analgésicos no Narcóticos/normas , Asma/inducido químicamente , Asma/epidemiología , Asma/prevención & control , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/prevención & control , Dolor Crónico/etiología , Femenino , Humanos , Incidencia , Cuidados a Largo Plazo/métodos , Cuidados a Largo Plazo/normas , Exposición Materna/efectos adversos , Trastornos del Neurodesarrollo/inducido químicamente , Trastornos del Neurodesarrollo/epidemiología , Trastornos del Neurodesarrollo/prevención & control , Estudios Observacionales como Asunto , Guías de Práctica Clínica como Asunto , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/epidemiología , Efectos Tardíos de la Exposición Prenatal/prevención & control , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo/métodosRESUMEN
Physical health monitoring is crucial in the light of current knowledge about the risks associated with schizophrenia and its treatment. Cooperation between psychiatrists, patients and informal carers can significantly enhance patient wellbeing in this regard. Moreover, an advocacy approach elevates patients from being passive recipients of care to active participants in an integrated system that has outcome benefits for all stakeholders. Considerable progress is being made in this regard, although there is still a long way to go to maximise the benefits of carer involvement in the global management of schizophrenia.
Asunto(s)
Antipsicóticos/efectos adversos , Cuidadores/psicología , Estado de Salud , Relaciones Profesional-Familia , Esquizofrenia/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antipsicóticos/uso terapéutico , Organizaciones del Consumidor , Conducta Cooperativa , Femenino , Humanos , Comunicación Interdisciplinaria , Masculino , Persona de Mediana Edad , Defensa del Paciente , Educación del Paciente como Asunto , Prejuicio , Apoyo Social , Adulto JovenRESUMEN
Improved physical health care is a pressing need for patients with schizophrenia. It can be achieved by means of a multidisciplinary team led by the psychiatrist. Key priorities should include: selection of antipsychotic therapy with a low risk of weight gain and metabolic adverse effects; routine assessment, recording and longitudinal tracking of key physical health parameters, ideally by electronic spreadsheets; and intervention to control CVD risk following the same principles as for the general population. A few simple tools to assess and record key physical parameters, combined with lifestyle intervention and pharmacological treatment as indicated, could significantly improve physical outcomes. Effective implementation of strategies to optimise physical health parameters in patients with severe enduring mental illness requires engagement and communication between psychiatrists and primary care in most health settings.
Asunto(s)
Antipsicóticos/efectos adversos , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Cardiovasculares/epidemiología , Conducta Cooperativa , Estado de Salud , Hiperprolactinemia/inducido químicamente , Hiperprolactinemia/epidemiología , Comunicación Interdisciplinaria , Tamizaje Masivo , Grupo de Atención al Paciente , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/epidemiología , Antipsicóticos/uso terapéutico , Enfermedades Cardiovasculares/prevención & control , Comorbilidad , Conductas Relacionadas con la Salud , Humanos , Hiperprolactinemia/prevención & control , Estilo de Vida , Anamnesis , Examen FísicoRESUMEN
Seven of one hundred twenty-one patients with chronic myeloid leukemia (CML) treated with imatinib mesylate developed subdural hematomas. All had advanced disease and were treated initially at a dose of 600 mg per day. Three patients had thrombocytopenia (platelet < 10 x 10(9)/l), one had leukocytosis (white blood cell count > 150 x 10(9)/l) and three had neither around the time of diagnosis of the subdural hematomas. Four patients required surgical evacuation. One patient, in blast crisis, died as a consequence of the subdural hematoma. Three patients survived but died of progressive CML. The remaining three patients having recommenced imatinib, are alive and well, and one has achieved a major cytogenetic response. Subdural hematomas must be considered even in mildly symptomatic patients receiving imatinib regardless of their peripheral blood counts. Patients who survive can be cautiously restarted on imatinib. Further studies are required to study the potential relationship between imatinib mesylate and subdural hematomas.
Asunto(s)
Antineoplásicos/efectos adversos , Hematoma Subdural/inducido químicamente , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Piperazinas/efectos adversos , Pirimidinas/efectos adversos , Anciano , Benzamidas , Crisis Blástica/inducido químicamente , Crisis Blástica/tratamiento farmacológico , Femenino , Hematoma Subdural/complicaciones , Hematoma Subdural/tratamiento farmacológico , Humanos , Mesilato de Imatinib , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Leucemia Mielógena Crónica BCR-ABL Positiva/cirugía , Leucocitosis/inducido químicamente , Masculino , Persona de Mediana Edad , Inducción de Remisión , Factores de Riesgo , Trombocitopenia/inducido químicamente , Resultado del TratamientoRESUMEN
OBJECTIVE: To determine the prevalence of pica and its characteristics among children with sickle cell disease. DESIGN: Retrospective, observational study. SETTING: An urban, ambulatory care, interdisciplinary center. PATIENTS: The medical records of all 480 patients who visited the center from March 1, 1998, to June 30, 1999, were reviewed. Patients were excluded for history of stroke, long-term transfusions, pregnancy, acute illness, or age younger than 3 years. MAIN OUTCOME MEASURES: Sex, age, weight, height, Tanner stage, complete blood cell count, sickle cell genotype, pica history, and levels of iron, zinc, lead, and fetal hemoglobin (Hb). RESULTS: Of 395 study patients, 134 (33.9%) reported pica. Ingested items included paper, foam, and powders. There was a significantly higher prevalence of pica among patients homozygous for Hb S (Hb SS, sickle cell anemia) compared with the combined group of double heterozygous patients with Hb SC, Hb SD, and Hb Sbeta thallasemia (Sbeta(+)or Sbeta(0)) (35.6% vs 25.5%; P =.03). Within genotype, mean Hb levels were significantly lower and reticulocyte counts were significantly higher in the patients with pica. Overall, the mean age of patients with pica was significantly lower; however, the prevalence was 23.3% (27/116) among those aged 10.0 to 14.9 years and 14.8% (8/54) among those aged 15.0 to 19.0 years. Within age groups, patients with pica weighed significantly less. CONCLUSIONS: Pica appeared to have an unusually high prevalence in patients with sickle cell disease and a correlation with lower Hb levels. It is unclear whether pica is a specific marker of disease severity, because our review did not show a relationship to increased number and duration of hospitalizations. The association between pica and low body weight suggests a nutritional effect on its prevalence.
Asunto(s)
Enfermedad de la Hemoglobina SC/epidemiología , Pica/epidemiología , Adolescente , Adulto , Niño , Preescolar , Comorbilidad , Femenino , Enfermedad de la Hemoglobina SC/sangre , Hemoglobinas/análisis , Humanos , Masculino , Pica/sangre , Prevalencia , Estudios RetrospectivosRESUMEN
PURPOSE: To determine the frequency of return of ovarian function after autologous bone marrow transplantation (ABMT), and the major factors that predict recovery. PATIENTS AND METHODS: Records of 200 consecutive women who underwent ABMT at the University of Toronto Autologous Blood and Marrow Program (Toronto, Canada) were reviewed. Seventeen patients met the inclusion criteria, which were (1) alive at the time of evaluation, (2) disease-free at least 18 months after transplantation, (3) age younger than 50 years at transplantation, and (4) premenopausal before transplantation. Recovery of ovarian function was determined by pregnancy or regular menses, with no menopausal symptoms and an estradiol level greater than 20 pmol/L off hormonal therapy. RESULTS: All 17 patients became menopausal immediately after ABMT. Five patients (29%) recovered ovarian function a median of 24 months post-ABMT (range, 6 to 48 months). The median age at transplantation of women with restored ovarian function was 19 years (range, 19 to 28 years) versus 30 years (range, 22 to 48 years) for those who did not regain function. Younger age at transplantation predicted ovarian recovery (P = .03) by means of a log-rank test. Only one of five women who regained ovarian function received total-body irradiation (TBI) compared with five of 12 women who did not. Univariate analysis suggested a trend for TBI to predict a sustained loss of ovarian function (P = .067). The number of regimens of induction or salvage chemotherapy that contained an alkylating agent ranged from none to five and was not predictive (P = .45). CONCLUSION: All women became menopausal after ABMT but 29% recovered ovarian function. Younger age at transplantation predicted return of ovarian function, whereas TBI may have had a negative effect.
Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Ovario/fisiopatología , Insuficiencia Ovárica Primaria/etiología , Análisis Actuarial , Adulto , Factores de Edad , Estradiol/sangre , Femenino , Humanos , Menstruación , Persona de Mediana Edad , Pruebas de Función Ovárica , Embarazo , Insuficiencia Ovárica Primaria/sangre , Insuficiencia Ovárica Primaria/fisiopatología , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Trasplante Autólogo , Resultado del TratamientoRESUMEN
People with sickle cell disease (SCD) vary in their pain, activity levels, and medical care. We examined how coping (Coping Strategies Questionnaire), somatic awareness, and illness worry were related to these health indices in 70 African-American adults with SCD. Negative Thinking/Passive Adherence and/or somatic awareness was positively correlated with pain episode frequency, duration, or severity, after controlling for demographics and disease severity and positively correlated with activity reduction or hospitalization frequency after also controlling for pain. Self-reported negative affectivity was correlated with both psychological and SCD measures; and controlling for negative affectivity eliminated several, but not all, relationships. Examination of the Negative Thinking/Passive Adherence factor suggested a distinction between Negative Thinking and Passive Adherence, which was partially supported by their different relationships. We conclude that negative thinking, passive coping, and somatic awareness are related to several measures of poor health in SCD but that some relationships are better accounted for by general measures of negative affectivity.
Asunto(s)
Adaptación Psicológica , Anemia de Células Falciformes/psicología , Concienciación , Depresión/psicología , Estado de Salud , Dolor/psicología , Rol del Enfermo , Trastornos Somatomorfos/psicología , Actividades Cotidianas/psicología , Adolescente , Adulto , Negro o Afroamericano/psicología , Población Negra , Depresión/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Trastornos Somatomorfos/diagnósticoRESUMEN
We performed a pilot study of human recombinant IL-6 (SDZ ILs 969) in 6 patients with poor prognosis Hodgkin's disease following autologous bone marrow transplantation (ABMT) to determine its safety and tolerability. IL-6 was administered the day following bone marrow infusion by subcutaneous injection once daily at a dose of 1 micro/kg/day to 3 patients and 2.5 microg/kg/day to 3 patients and was continued for 6 weeks or until platelet engraftment (>50 x 10(9)/L independent of transfusion). No severe or life threatening toxicities were seen at either dose level. A reversible elevation in alkaline phosphatase occurred in 4 patients and all patients complained of headache, myalgias, and fever. Gastrointestinal toxicity was low, grade 3-4 mucositis occured less frequently than in similarly-treated historical controls receiving GM-CSF. Serum concentrations of other cytokines such as IL-3 and G-CSF after ABMT differed from results obtained in transplant recipients given GM-CSF. The median time to an ANC >0.5 x 10(9)/L was 25.5 days and to a platelet count of >20 x 10(9)/L independat of transfusion was 35.5 days. Engraftment was no different from controls. Five patients relapsed at a median of 5 months post-ABMT and four remain alive at a median of 12 months post-ABMT. We conclude that IL-6 administration is safe and well tolerated in patients following ABMT. Further efforts to evaluate its effect on hematopietic recovery as well as relapse following transplantation in a larger patient series are warranted.
Asunto(s)
Trasplante de Médula Ósea , Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/terapia , Interleucina-6/uso terapéutico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bleomicina/administración & dosificación , Terapia Combinada , Citocinas/sangre , Dacarbazina/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Células Madre Hematopoyéticas/efectos de los fármacos , Enfermedad de Hodgkin/sangre , Humanos , Interleucina-6/efectos adversos , Masculino , Mecloretamina/administración & dosificación , Proyectos Piloto , Prednisona/administración & dosificación , Procarbazina/administración & dosificación , Pronóstico , Proteínas Recombinantes/uso terapéutico , Trasplante Autólogo , Vinblastina/administración & dosificación , Vincristina/administración & dosificaciónRESUMEN
Parenteral nutrition support is the provision of essential nutrients intravenously, bypassing the intestinal tract. It is used in a variety of clinical settings and medical conditions. Parenteral nutrition is a complex technology that requires the input of many professionals, including dietitians. The role of the dietitian in parenteral nutrition support involves direct patient care, consultative services, education, program development, and research. Even though this field of practice is still developing, some common practices can be described. Nutrition assessment determination of macronutrient and micronutrient requirements, and monitoring are vital aspects of the provision of parenteral nutrition support that benefit from the knowledge and experience of a dietitian. The future of parenteral nutrition includes identification of preferred fuels for specific disease states, development of new lipid emulsions, and identification of conditionally essential nutrients.
Asunto(s)
Nutrición Parenteral en el Domicilio , Nutrición Parenteral , Dietética/tendencias , Metabolismo Energético , Emulsiones Grasas Intravenosas , Humanos , Hidrolisados de Proteína , Estados UnidosRESUMEN
PURPOSE: To evaluate an intensive therapy regimen of high-dose etoposide and melphalan and autologous bone marrow transplantation (ABMT) in advanced Hodgkin's disease; and to determine possible prognostic factors that predict for long-term disease-free survival (DFS). PATIENTS AND METHODS: Seventy-three patients with advanced Hodgkin's disease who had failed to achieve remission with front-line chemotherapy (n = 16) or who had relapsed (n = 57) were treated with high-dose etoposide 60 mg/kg and melphalan 160 mg/m2 and ABMT. Previous therapy included mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), or hybrid MOPP/ABV. All patients received pretransplant cytoreduction with conventional-dose salvage chemotherapy and 40 also received pretransplant extended-field radiation to areas of bulky nodal disease (> 5 cm). RESULTS: Response to high-dose etoposide and melphalan was determined at 3 months post-ABMT. The complete response (CR) rate was 75% (95% confidence interval [CI], 64% to 84%), including 35 of 50 patients with measurable disease before ABMT (70%; 95% CI, 60% to 86%). There were three early deaths (septicemia) and four late deaths (three interstitial pneumonitis, one intracerebral hemorrhage). Actuarial DFS is 38.6% at 4 years. Multivariate regression analysis showed that disease status at the time of ABMT (no evidence of disease [NED], nonbulky residual disease [NBRD], or bulky disease) was the most important factor determining DFS: 68% of those transplanted with NED versus 26% for patients with NBRD and 0% for bulky disease (P = .0002, log-rank test). Relapse in a previous radiation field was the only other significant prognostic factor. CONCLUSION: Etoposide and melphalan is an effective and well-tolerated intensive therapy regimen in advanced Hodgkin's disease. Patients in complete remission after conventional-dose salvage therapy transplanted with this regimen enjoy superior long-term DFS.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Médula Ósea , Enfermedad de Hodgkin/terapia , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Trasplante de Médula Ósea/efectos adversos , Terapia Combinada , Etopósido/administración & dosificación , Etopósido/efectos adversos , Femenino , Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/mortalidad , Enfermedad de Hodgkin/cirugía , Humanos , Masculino , Melfalán/administración & dosificación , Melfalán/efectos adversos , Persona de Mediana Edad , Tasa de SupervivenciaRESUMEN
Recombinant human interleukin-3 (IL-3) is well-tolerated according to phase I studies, and produces trilineage hematologic responses in patients with normal bone marrow. In addition, promising results have been obtained in a variety of bone marrow failure states. We studied IL-3 in 7 patients with markedly delayed engraftment after autologous bone marrow transplantation (ABMT) for hematologic malignancies (acute myeloid leukemia 4, chronic myeloid leukemia 1, myeloma 1, non-Hodgkin's lymphoma 1). All patients were red blood cell- and platelet transfusion-dependent, had an absolute neutrophil count (ANC) < 0.7 x 10(9)/L and failed to achieve a sustained ANC > 1.0 x 10(9)/L after receiving granulocyte-macrophage colony stimulating factor (GM-CSF) for 28 days. IL-3 was given daily for 21 days at 2 micrograms/kg/d (2 patients) and 5 micrograms/kg/d (5 patients). Toxicity was mild and consisted mostly of low-grade fever and malaise. No changes in platelet, hemoglobin or reticulocyte levels were observed. Four patients had at least a 2-fold increase in ANC at the end of IL-3 treatment. Five patients received GM-CSF 10 micrograms/kg/d subcutaneously for 7 to 10 days immediately after IL-3 and 4 had a further increase in ANC (median 1.7-fold, range 1.6- to 5.8-fold), but no change in platelet transfusion requirements. Hematopoietic colony assays of bone marrow cells obtained before and after treatment showed that granulocyte-macrophage colony-forming cell (CFU-GM) and erythroid blast-forming cell (BFU-E) levels were severely reduced and multilineage progenitors (CFU-GEMM) absent in all patients, and remained low after IL-3 treatment for 21 days. Sequential IL-3 and GM-CSF produced a significant but transient increase in the neutrophil counts of some patients. IL-3 appears to be of limited benefit in patients who are severely aplastic after ABMT and have very low levels of bone marrow progenitors.
Asunto(s)
Trasplante de Médula Ósea , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Interleucina-3/uso terapéutico , Enfermedad Aguda , Adulto , Recuento de Células Sanguíneas/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , División Celular/efectos de los fármacos , División Celular/fisiología , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Femenino , Rechazo de Injerto , Factor Estimulante de Colonias de Granulocitos y Macrófagos/efectos adversos , Granulocitos/citología , Granulocitos/efectos de los fármacos , Granulocitos/fisiología , Hematopoyesis/efectos de los fármacos , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/fisiología , Humanos , Interleucina-3/efectos adversos , Leucemia Mielógena Crónica BCR-ABL Positiva/cirugía , Leucemia Mieloide/cirugía , Linfoma no Hodgkin/cirugía , Masculino , Persona de Mediana Edad , Mieloma Múltiple/cirugía , Neutrófilos/citología , Neutrófilos/efectos de los fármacos , Neutrófilos/fisiología , Proteínas Recombinantes/uso terapéutico , Factores de Tiempo , Trasplante AutólogoRESUMEN
Home enteral nutrition support is a rapidly expanding area providing new challenges for the clinical dietitian. It begins with identification of appropriate candidates based on their physical condition, home environment, and goals of therapy. A thorough nutrition assessment is performed to determine macronutrient and micronutrient needs. Considerations for formula selection include the form and source of nutrients, cost, and goals of therapy. Administration may be by a bolus, intermittent gravity drip, continuous infusion, or cyclic infusion method. Selection of an appropriate access route should consider the length of therapy, medical condition, pathology of the gastrointestinal tract, and the infusion method. Discharge teaching should stress maintenance of the patency and tube position, accurate formula delivery, and proper use of equipment and supplies. Issues involving reimbursement and financial responsibility should be addressed before the home therapy is initiated. Home patients should be monitored and reassessed regularly to update the plan of care and goals of therapy. Vendors should be selected on the basis of their capability to meet the patient's needs. If all phases are implemented, home enteral nutrition is a safe and acceptable means of nutrient delivery.
Asunto(s)
Nutrición Enteral/métodos , Atención Domiciliaria de Salud , Diarrea/etiología , Nutrición Enteral/efectos adversos , Nutrición Enteral/economía , Humanos , Estado Nutricional , Alta del Paciente , Neumonía por Aspiración/etiologíaRESUMEN
Lysophosphatidic acid (LPA) is a lysophospholipid that is produced during thrombin stimulation of platelets, which can promote platelet aggregation. The mechanism of the effect of LPA was explored in normal platelets and in platelets from a patient with a storage pool deficiency (SPD). A comparison with other lysophospholipids showed that only LPA exerted significant effects to cause or potentiate platelet aggregation. Aspirin, an inhibitor of prostaglandin endoperoxide synthetase, had little effect on LPA-induced aggregation, but completely blocked LPA-induced serotonin secretion. LPA also promoted phosphorylation of myosin light chain (MLC), a 47 kilodalton (kDa) protein, and actin-binding protein. Aspirin significantly inhibited the phosphorylation of the 47-kDa and actin-binding proteins at 3-8 min after the addition of LPA, but had no effect on protein phosphorylation within the 1st min and had no significant effect on MLC phosphorylation. In SPD platelets, aspirin partially inhibited both aggregation and phosphorylation of the 47-kDa protein (less than 30% inhibition) and MLC (less than 40% inhibition) at time points of 1 min or less. The addition of ADP to SPD platelets enhanced the LPA response in platelets either pretreated or not pretreated with aspirin. Studies with SPD platelets indicate that thromboxane and secreted ADP contribute to, but are not necessary for, LPA-induced aggregation and phosphorylation. A23187 (a calcium ionophore) and LPA showed some selectivity to promote MLC as opposed to the 47-kDa protein phosphorylation, particularly at low concentrations of agonists and at earlier time points. The protein phosphorylation changes seen are consistent with a role for MLC phosphorylation in the granule centralization promoted with LPA.
Asunto(s)
Plaquetas/metabolismo , Proteínas Sanguíneas/metabolismo , Lisofosfolípidos/farmacología , Adulto , Plaquetas/efectos de los fármacos , Humanos , Cinética , Errores Innatos del Metabolismo Lipídico/sangre , Masculino , Fosfolípidos/farmacología , Fosforilación , Agregación Plaquetaria/efectos de los fármacos , SíndromeRESUMEN
The influence on pancreatic secretion of four enteral feeding products was evaluated in a unique patient with an isolated duodenal fistula for whom enteral feeding access was obtained via a gastrostomy with a small Silastic catheter passed through the gastrostomy and through a surgically created gastrojejunostomy. The patient was totally supported by intravenous nutrition during the study. Each enteral feeding solution was administered at full strength at 50 ml/hr for 2 days with a 24-hr collection of pancreatic secretions by the duodenal cutaneous fistula taken on the second day. Infusion of the enteral feeding solutions did not alter volume of fistula drainage. All solutions decreased bicarbonate and amylase secretion but increased lipase and total nitrogen excretion. From this study, it would appear reasonable to administer Vivonex HN and Criticare HN via the jejunum in patients with pancreatic disease, whereas Osmolite would appear less satisfactory, due to its much stronger stimulation of lipase secretion.
Asunto(s)
Nutrición Enteral , Páncreas/metabolismo , Colelitiasis/cirugía , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Aire/análisis , Dimetilnitrosamina/análisis , Nitrosaminas/análisis , Industrias , Maryland , West VirginiaRESUMEN
Gram-negative septicemia was induced in rats by two daily injections of fecal mixture into the thigh, after which the thyroid function was markedly suppressed for 2 days. Iodine metabolism was studied by organ radioassay and by imaging with a multiwire proportional chamber (MWPC) at various time intervals after intravenous injection of 125I. Plasma T3, T4, and TSH, measured by radioimmunoassays, were suppressed, as were the T3-resin uptakes. Fractional blood supply to the thyroid glands of the infected rats, studied by the 81Rb uptake method, was also found to be markedly reduced. Sections of the thyroid glands showed little structural change during the period of marked thyroid suppression. There was no biochemical evidence of renal failure in the septicemic rats.